A family with the Arg103Pro mutation in the NEUROD1 gene detected by next-generation sequencing - Clinical characteristics of mutation carriers

详细信息    查看全文

• 作者：Magdalena Szopa^a ; ^b ; ¹ ; Agnieszka H. Ludwig-Galezowska^a ; ^c ; ¹ ; Piotr Radkowski^c ; Jan Skupien^a ; ^c ; Julita Machlowska^c ; Tomasz Klupa^a ; ^b ; Pawel Wolkow^c ; Maciej Borowiec^d ; Wojciech Mlynarski^e ; Maciej T. Malecki^a ; ^b ; ^{maciej.malecki@uj.edu.pl" class="auth_mail" title="E-mail the corresponding author} ; ^{malecki_malecki@yahoo.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Diabetes ; MODY ; NEUROD1
• 刊名：European Journal of Medical Genetics
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：59
• 期：2
• 页码：75-79
• 全文大小：335 K

文摘

Until now only a few families with early onset autosomal diabetes due to the NEUROD1 gene mutations have been identified. Moreover, only some of them meet strict MODY (maturity-onset diabetes of the young) criteria. Next-generation sequencing (NGS) provides an opportunity to detect more pathogenic mutations in this gene.

Here, we evaluated the segregation of the Arg103Pro mutation in the NEUROD1 gene in a pedigree in which it was detected, and described the clinical characteristics of the mutation carriers.

Methods

We included 156 diabetic probands of MODY families, among them 52 patients earlier tested for GCK-MODY and/or HNF1A-MODY by Sanger sequencing with negative results. Genetic testing was performed by targeted NGS sequencing using a panel of 28 monogenic diabetes genes.

Results

As detected by NGS, one patient had the missense Arg103Pro (CGC/CCC) mutation in the gene NEUROD1 changing the amino-acid structure of the DNA binding domain of this transcription factor. We confirmed this sequence difference by Sanger sequencing. This family had previously been tested with negative results for HNF1A gene mutations. 17 additional members of this family were invited for further testing. We confirmed the presence of the mutation in 11 subjects. Seven adult mutation carriers (all but one) from three generations had been already diagnosed with diabetes. There were 3 individuals with the Arg103Pro mutation diagnosed before the age of 30 years in the family. The range of age of the four unaffected mutation carriers (3 minors and 1 adult) was 3–48 years. Interestingly, one mutation carrier had a history of transient neonatal hypoglycemia, of which the clinical course resembled episodes typical for HNF4A-MODY.

Conclusions

We report a family with autosomal dominant diabetes related to a new NEUROD1 mutation, one of very few meeting MODY criteria. The use of the NGS method will facilitate identification of more families with rare forms of MODY.